GW Pharma’s Epidiolex sales grow, but so do Q3 losses
GW Pharmaceuticals had sales of $132.6 million (~€113 million) for its CBD-based drug Epidiolex in the third quarter of the year, driven mostly by U.S. sales. The UK-based company said […]
GW Pharma’s Epidiolex sales grow, but so do Q3 losses Read More »